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Abstract
Background: Little is known about who the main public and philanthropic funders of health research are globally,
what they fund and how they decide what gets funded. This study aims to identify the 10 largest public and
philanthropic health research funding organizations in the world, to report on what they fund, and on how they
distribute their funds.
Methods: The world’s key health research funding organizations were identified through a search strategy aimed at
identifying different types of funding organizations. Organizations were ranked by their reported total annual health
research expenditures. For the 10 largest funding organizations, data were collected on (1) funding amounts
allocated towards 20 health areas, and (2) schemes employed for distributing funding (intramural/extramural,
project/‘people’/organizational and targeted/untargeted funding). Data collection consisted of a review of reports
and websites and interviews with representatives of funding organizations. Data collection was challenging; data
were often not reported or reported using different classification systems.
Results: Overall, 55 key health research funding organizations were identified. The 10 largest funding organizations
together funded research for $37.1 billion, constituting 40% of all public and philanthropic health research
spending globally. The largest funder was the United States National Institutes of Health ($26.1 billion), followed by
the European Commission ($3.7 billion), and the United Kingdom Medical Research Council ($1.3 billion). The
largest philanthropic funder was the Wellcome Trust ($909.1 million), the largest funder of health research through
official development assistance was USAID ($186.4 million), and the largest multilateral funder was the World
Health Organization ($135.0 million). Funding distribution mechanisms and funding patterns varied substantially
between the 10 largest funders.
Conclusions: There is a need for increased transparency about who the main funders of health research
are globally, what they fund and how they decide on what gets funded, and for improving the evidence base for
various funding models. Data on organizations’ funding patterns and funding distribution mechanisms are often
not available, and when they are, they are reported using different classification systems. To start increasing
transparency in health research funding, we have established www.healthresearchfunders.org that lists health
research funding organizations worldwide and their health research expenditures.
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Background
Approximately 40% of all health research in high-
income countries is funded by public and philanthropic
funding organizations [1]. These organizations play a
central role in the development of new knowledge and
products, particularly in areas that are not sufficiently
profitable [2]. For example, the involvement of public
and philanthropic funding organizations has been key in
the development of new medical products to combat
neglected diseases [1, 2] and, since recently, these orga-
nizations are increasingly taking action to address the
lack of development of new antibiotics [3–5].
Transparency on who the main funding organizations
of health research are, on what they fund (their funding
patterns) and on how they decide on what gets funded
(their priority setting mechanisms and funding distribu-
tion mechanisms) can help funding organizations to
synchronize their efforts, potentially preventing the dupli-
cation of research and improving collaboration on re-
search priorities, and has various other strategic and
practical benefits for funders [2, 6–12]. Such transparency
also allows for external evaluation of funding organiza-
tions’ portfolios and decision-making processes [7, 13].
This is particularly important for public funding organiza-
tions, since they distribute public funds. For philanthropic
funders, such accountabilities are less clear, but given the
substantial impact of some of these funders on the global
landscape for health research, it might be reasonable to
make similar demands from this group of funders [14, 15].
Although substantial insight has been created in
recent years into countries’ expenditures on health re-
search [1, 16–20], there has been relatively little scrutiny
of the funding patterns and mechanisms of individual
funding organizations. Mappings of individual funding or-
ganizations’ expenditures on health research are often lim-
ited to one or several countries [7, 10, 21–26] or to a
select group of diseases [25, 27–29]. To increase the avail-
able information on major public and philanthropic fun-
ders of health research, we present a mapping in this
article that had a simple target: to identify the 10 largest
public and philanthropic funders of health research in the
world, to report on what they fund, and on their mecha-
nisms for distributing these funds (funding organizations’
priority setting mechanisms were beyond the scope of this
study – see Limitations section for more detail).
Methods
Here, we outline the methods used to identify the 10 lar-
gest funding organizations of health research in the
world, and to assess the funding patterns and funding
distribution mechanisms of these organizations. A more
detailed description of these methods is provided in
Additional file 1. All data were collected from November
4, 2013, to August 12, 2014.
Identifying the 10 largest funders of health research
Search strategy
This study distinguished between four types of public
and philanthropic health research funders: (1) public na-
tional or regional funders (excluding funders of official
development assistance (ODA) and multilateral funders),
(2) philanthropic funders, (3) ODA funders, and (4)
multilateral funders. The mandate of the funding body
did not need to be limited to funding health research.
Funding organizations were identified through a search
strategy that had several components: key funding orga-
nizations in the 20 countries with the highest spending
on health research [1] were identified, membership lists
of collaborative groups of funders (i.e. groups where
major funders of health research collaborate on a global
or regional level) were reviewed, publicly available lists
of funding organizations that included annual spending
on health research were searched, and data on Develop-
ment Assistance for Health were used to identify key
ODA funders. For every funder type, a specific search
strategy was used to identify the largest funders of health
research (Additional file 1). Private for-profit funding or-
ganizations were not included in our analysis; we only
aimed to map public and philanthropic funders (private
for-profit health research funders are mapped elsewhere
[30]). Product development partnerships (PDPs) and other
public private partnerships (PPPs) were also excluded be-
cause they are intermediate funding organizations, who
are funded in turn by governments, philanthropies and
the for-profit sector. Furthermore, we excluded single dis-
ease funders; although the majority of philanthropic fun-
ders of health research focuses on one disease [21], the
largest philanthropic funders of health research tend to
fund across multiple disease areas (with some exceptions
[31, 32]). We note that the annual health research expendi-
tures of the largest PDP, PPP and single-disease funders
that we are aware of are lower than the annual expenditures
of the 10 largest public and philanthropic funders reported
in this study (see Additional file 1). Finally, in two cases
(the United States Department of Defense (US DoD) and
the European Commission (EC)) we included both the
overarching organization at its largest sub-organizations
or sub-programmes, because of the substantial differences
between the funding distribution mechanisms of these
sub-organizations and sub-programmes.
To aid future analyses of this kind, we provide an
overview of various sources that helped us identify the
main public and philanthropic funders of health research
globally in Additional file 2.
Assessing health research expenditures
For all the funding organizations that followed from our
search, publicly available data were collected on the or-
ganizations’ annual health research expenditures (from
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annual reports and websites). Data were collected for
the most recent year available. When we were not able
to find data on organizations’ annual expenditures in the
public domain, we contacted funders to ask if they could
provide us with their annual expenditures on health
research.
Funding organizations differ on at least three aspects
in terms of how they report their annual health research
expenditures. First, expenditures can be reported as ac-
tual expenditures, commitments or budgets. Second,
there can be differences in terms of what the expendi-
tures cover. They can cover the organization’s total ex-
penditures on health research excluding operational
costs (for managing the funding organization), its total
expenditures including operational costs, or its total
overall turnover over a single fiscal year (this was only
collected if the funding organization exclusively funded
health research). Third, there can be differences in terms
of the research areas that the reported expenditures per-
tain to: only health research, or broader categories such as
health and biological research or life sciences research.
For each funder we extracted data on annual health re-
search expenditures in a step-wise manner, always report-
ing the actual expenditures excluding operational costs in
the area of health research when possible. When these
numbers were not available, we reported the next best
available number, following the order in the categories
provided above. We note that the data from the funding
organizations in the top 10 all relate only to health re-
search, all concern actual expenditures or commitments,
and for all, except one, operational costs were excluded.
Training support and research education were not in-
cluded in the overall amount for health research expen-
ditures. In addition, for government ministries, we
excluded two types of funding flows. First, when funding
was provided by ministries to funding agencies for distri-
bution, we included the funding for the funding agencies,
but not for the ministries. Second, for government minis-
tries, such as ministries of education or health, we ex-
cluded block funding to universities or hospitals (similar
to other initiatives that have reported on health research
funding flows [24]). For funding agencies, we did include
institutional funding.
Finally, organizations’ expenditures were made com-
parable using methods by Young et al. [17, 20]. To do
so, we first deflated organizations’ expenditures in the
national currency to the year 2013 using Gross Domestic
Product deflators from the International Monetary Fund
World Economic Outlook Database of April 2014 [33].
Second, we converted the inflation-corrected expendi-
tures to US dollars using the World Bank Official ex-
change rates for the year 2013. As a secondary outcome,
we calculated funding organizations’ health research ex-
penditures as 2013 purchasing power parity-adjusted US
dollars (these are not reported in this article, but are
available on www.healthresearchfunders.org) [17, 20].
Assessing the funding patterns and funding distribution
mechanisms of the 10 largest funders of health research
After the 10 largest funding organizations of health re-
search were identified, data were collected on their fund-
ing patterns and funding distribution mechanisms. For
each organization, data were collected on:
1. The funding mechanisms used to distribute funding:
intramural funding or extramural funding. For
extramural funding, we distinguished between
project grants, ‘people grants’, programme grants,
funding distributed to organizations and other
extramural research funding. For project grants,
data were collected to assess if the distribution
was untargeted, targeted or highly targeted (for
definitions see Additional file 1).
2. The amount of funding allocated to a list of 20 key
health areas from the Global Burden of Disease
classification [34].
Funding for operational expenditures was excluded.
Finally, we denoted whether funding organizations
used a classification system to classify funding to various
health areas and whether they reported statistics on fund-
ing for various research types (e.g. biomedical research,
clinical research, epidemiological research or health sys-
tems research [35]) and recipient countries or regions.
All data were collected from online reporting databases,
annual reports, official websites, or other information
sources. After this, each funder was invited to participate
in an interview. Before the interview, a document with
collected data was made available to a representative of
the funder. Before and during the interviews, representa-
tives were asked to add, amend or confirm the data.
Results
Identifying the 10 largest funding organizations of health
research
Public and philanthropic funding organizations
Our search identified 55 public and philanthropic fun-
ders that were candidates for being one of the 10 largest
funders of health research in the world (Table 1), exclud-
ing ODA funders and multilaterals (we searched separ-
ately for these and report on them later). For 41
organizations, data on the organizations’ annual health
research expenditures were available. For five of these
organizations, this information was received through
personal communications (not publicly reported). Four-
teen funders did not provide figures about their annual
health research expenditures. Often, these organizations
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Table 1 Annual health research expenditures of 55 major public and philanthropic funders of health research
# Public and philanthropic health
research funding organizations
Country Type of
funding
organization
Year for which
funding data were
collected
Total health research
expenditures
(in million 2013 US $)
Specificity of the
funding dataa
Research area
that the funding
data refer toa
Reporting format
of the funding
dataa
1 National Institutes of Health (NIH) USA Public 2013 26,081.3 I A 1
2 European Commission (EC)b EU Public 2013 3717.7 II A 1
2a FP7 - Cooperation programme - Health Theme/Health Directoratec EU Public 2013 1181.7 II A 1
2b European Research Council (ERC) EU Public 2013 783.4 II A 1
3 UK Medical Research Council (MRC) GBR Public 2013 1321.5 I A 1
4 Institut national de la santé et de la
recherche médicale (Inserm)
FRA Public 2013 1041.2 I A 1
5 United States Department of Defense (US DoD)b USA Public 2013 1017.7 I A 2
5a Congressionally Directed Medical Research Program (CDMRP) USA Public 2012 409.0 I A 1
6 Wellcome Trustd GBR Philanthropic 2013 909.1 I A 1
7 Canadian Institutes of Health Research (CIHR) CAN Public 2012 883.6 I A 1
8 Australian National Health and Medical Research Council (NHMRC) AUS Public 2013 777.6 I A 1
9 Howard Hughes Medical Institute (HHMI) USA Philanthropic 2013 752.0 I A 1
10 Deutsche Forschungsgemeinschaft / German Research Foundation
(DFG)
DEU Public 2012 630.6 I A 1
11 National Natural Science Foundation of China (NSFC) CHN Public 2012 621.3 II A 1
12 Centre National de la Recherche Scientifique (CNRS) FRA Public 2013 531.0 III B 2
13 UK Department of Health / National Institute for Health
Research (NIHR)
GBR Public 2012 491.2 I A 1
14 Japan Society for Promotion of Science (JSPS) JPN Public 2011 472.5 I A 1
15 Bundesministerium für Bildung und Forschung / Federal
Ministry of Education and Research of Germany (BMBF)
DEU Public 2013 472.1 I A 1
16 Bill & Melinda Gates Foundation (BMGF)e USA Philanthropic 2011 462.6 I A 1
17 Ministero della Salute / Ministry of Health of Italy ITA Public 2007 438.6 I A 2
18 Instituto de Salud Carlos III (ISCIII)e ESP Public 2011 388.2 I A 1
19 Ministry of Health of China CHN Public 2011 371.7 I A 1
20 Japan Science and Technology Agency (JST)e JPN Public 2012 338.5 I C 2
21 Institut Pasteur FRA Philanthropic 2013 220.9 I A 1
22 Singapore National Medical Research Council (NMRC) SGP Public 2012 220.7 – A 1
23 Korean National Research Foundation (NRF) KOR Public 2011 191.5 I A 1
24 Consejo Nacional de Investigaciones Científicas y
Técnicas (CONICET)e
ARG Public 2012 184.4 II B 1
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Table 1 Annual health research expenditures of 55 major public and philanthropic funders of health research (Continued)
25 Vetenskapsrådet-Medicine / Swedish Research Council SWE Public 2012 177.9 – A 1
26 Swiss National Science Foundation (SNSF) CHE Public 2012 172.9 I A 1
27 ZonMw / Netherlands Organisation for Health Research
and Development
NLD Public 2012 172.7 I A 1
28 Sao Paulo Research Foundation (FAPESP)e BRA Public 2012 154.2 I A 1
29 Indian Council of Medical Research (ICMR) IND Public 2011 140.3 I A 3
30 Fund for Scientific Research - Flanders (FWO) BEL Public 2010 136.9 I A 1
31 Korea National Institute of Health (KNIH) KOR Public 2013 120.0 III A 2
32 Forskingsrådet / Research Council of Norway NOR Public 2012 113.5 III A 2
33 Conselho Nacional de Desenvolvimento Científico
e Tecnológico (CNPq)
BRA Public 2013 110.8 I A 2
34 Fonds zur Förderung der wissenschaftlichen
Forschung / Austrian Science Fund (FWF)
AUT Public 2012 99.5 I C 1
35 South African Medical Research Council (SA MRC) ZAF Public 2012 63.2 I A 3
36 Health Research Council of New Zealand NZL Public 2012 61.6 III A 1
37 Danish Council for Independent Research / Medical Sciences DNK Public 2012 58.5 II A 1
38 Russian Foundation for Basic Research (RFBR) RUS Public 2013 53.6 III B 2
39 Danish Council for Strategic Research (two programmes:
Individuals, Disease and Society & Health, Food and Welfare)
DNK Public 2012 40.3 II C 1
40 Consejo Nacional de Ciencia y Tecnología (CONACYT) MEX Public 2010 21.9 II A 2
41 South African Department of Science and Technology (DST) ZAF Public 2012 13.5 I B 1
42 Agencia Nacional de Promocion Cientifica y Technologica
(Agenica - ANPCyT)
ARG Public – No data – – –
43 Biomedical Research Council of the Singapore Agency for Science,
Technology and Research (BMRC of A*STAR)
SGP Public – No data – – –
44 Ministry of Science and Technology of China (MOST) CHN Public – No data – – –
45 Indian Department of Biotechnology (DBT) IND Public – No data – – –
46 Indian Department of Science and Technology (DST) IND Public – No data – – –
47 King Abdulaziz City for Science and Technology (KACST) SAU Public – No data – – –
48 Le Fonds de la Recherche Scientifique (FNRS) BEL Public – No data – – –
49 Lipi Indonesian Research Council IDN Public – No data – – –
50 Ministry of Healthcare of the Russian Federation RUS Public – No data – – –
51 National Research Foundation South Africa (NRF SA) ZAF Public – No data – – –
52 Oswaldo Cruz Foundation (Fiocruz) BRA Philanthropic – No data – – –
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Table 1 Annual health research expenditures of 55 major public and philanthropic funders of health research (Continued)
53 Rockefeller foundation USA Philanthropic – No data – – –
54 Tubitak / Scientific and Technological Research Council of Turkey TUR Public – No data – – –
55 Turkish Academy of Sciences (TUBA) TUR Public – No data – – –
Total for the 10 largest funders of health research 37,132.2
Total for funders 11 to 41 7116.2
Total for all 41 funding organizations for which data were available 44,248.3
Dashes (“–”) indicate that no information was available. Funders of Official Development Assistance (ODA) and multilaterals funders are excluded from this table and are reported separately. Data presented in the
table are from the most recent year available at the time of data collection. Reported expenditures on health research can differ from what funders themselves report, because we excluded operational costs for
managing the funding organization where possible, and because we excluded funding for research education
aFunders report differently on their expenditures. Preferably, we collected information on the actual expenditures of a funder in the area of health research, excluding funders’ operational costs. However, this
information was not always available. Therefore, we describe here the type of data that we collected, in terms of how funding organizations report annual health research expenditures (i.e. I, actual expenditures; II,
commitments; or III, budgets), in terms of the research areas that their reported numbers pertain to (i.e. A, only health research; B, health and biological research; or C, life sciences research), and in terms of what the
expenditures cover (i.e. 1, total expenditures on health research excluding operational costs; 2, total expenditures on health research including also operational costs; or 3, total overall turnover for the funder over a
single fiscal year)
bTwo funders consisted of several sub-programmes with very different funding distribution mechanisms and patterns. (1) For the European Commission: Under the EC the FP7 was the largest research program in FY
2007–2013. The ERC and Cooperation programme - Health theme (the Health Directorate is the executive agency for the latter) are both programmes run under FP7. Under the FP7 there are several funding
programmes: Ideas – ERC, Cooperation programme, People – Marie Curie, Capacity Program, CIP and Euratom. Due to this large number of funding programmes, and the differences between the funding programmes,
we reviewed the two largest funding programmes: the Cooperation – Health theme and the Ideas – ERC programme. (2) For the US DoD: The defence health program holds 14 research programmes. We chose to
review the largest programme, which was identified as the CDMRP
cThe ERC was able to provide figures for its funding distribution mechanisms in the area of Life Sciences, not of health research. However, the website www.healthcompetence.eu provided figures of health research
funding by the ERC. For consistency, figures for the Health theme of the FP7 Cooperation programme were extracted from the same website. There are slight deviations between these figures and the health research
spending reported by FP7 Cooperation programme itself
dThe annual expenditures for the Wellcome Trust are a slight overestimation for health research spending. Under Medical Humanities and engagement, various non-research grants are provided as well as other
activities (e.g. running the Wellcome library), but these were not reported on separately, and are therefore included under ‘Research’
eInformation was collected from official websites and annual reports. For these five organizations, information was not publicly available, and was acquired through personal communication with a representative of
the organization
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were general funders of research and did provide overall
expenditure data but not for health research specifically.
For the 10 largest funders, health research funding
totalled to $ 37.1 billion, approximately 40% of all spend-
ing on health research globally by public and philan-
thropic sources [1]. The United States National Institutes
of Health (NIH) contributed the largest part of this
amount, with $ 26.1 billion in health research funding in
2013. The largest philanthropic funder was the Wellcome
Trust ($ 909.1 million). The Wellcome Trust and the
Howard Hughes Medical Institute (HHMI) were the only
two philanthropic funders among the 10 largest funders of
health research; the other eight organizations were public
funding bodies. All 10 funders came from Northern
America, Europe or Oceania. The largest Asian funding
organization identified was the National Natural Science
Foundation of China (NSFC) ($ 621.3 million), the largest
funder from Latin America and the Caribbean was
Consejo Nacional de Investigaciones Científicas y
Técnicas (CONICET) from Argentina ($ 184.4 million),
and the largest African funder was the South African
Medical Research Council (SA MRC) ($ 63.2 million).
ODA-agencies and multilaterals
The expenditures of ODA-agencies and multilaterals on
health research were substantially smaller than the expendi-
tures of the largest public and philanthropic funding orga-
nizations (Tables 2 and 3). The largest funder of health
research through ODA was USAID ($ 186.4 million) and
the largest multilateral funder was WHO ($ 135.0 million).
Assessing the funding patterns and funding distribution
mechanisms of the 10 largest funding organizations of
health research
Funding mechanisms used to distribute funding
There was considerable diversity in organizations’ fund-
ing distribution mechanisms (Table 4). Five funders
funded research fully extramurally, five allocated at least
a proportion of their funding to intramural research in-
stitutes, and one funder, the Institut national de la santé
et de la recherche médicale (Inserm), funded research
(almost) exclusively intramurally (total is 11 because for
the EC and the US DoD we analysed the sub-
organizations or sub-programmes: the US Congressionally
Directed Medical Research Program (CDMRP), the Health
theme of the EC FP7 Cooperation programme and the
European Research Council (ERC)).
Of the 10 funding organizations that provided extra-
mural funding, for six, the main mechanism for extra-
mural funding distribution was the allocation of funding
through untargeted competitive project or investigator
grants (often, there were also some smaller programmes
that used a more targeted distribution). Two funders,
the Health theme of the European Commission FP7
Cooperation programme and the US CDMRP, used a
more targeted approach and issued calls under priori-
tized areas. Funders also made use, in varying degrees,
of highly targeted funding schemes, such as research
contracts, tenders or prizes, but this was never the dom-
inant form of funding distribution. The last two funders,
the United Kingdom Medical Research Council (MRC)
and the Deutsche Forschungsgemeinschaft (DFG), used
a mixed approach to allocate funding, with substantial
contributions made through different funding distribu-
tion mechanisms. Lastly, the funding model of the NIH
and the untargeted part of the MRC deserve separate
mentioning because, although they adhered largely to an
untargeted model and research funding was available for
all areas of health research, the amounts of funding
available for various broad research areas were ear-
marked (in the case of the NIH, for example, through
budgets for the NIH institutes). This differs from tar-
geted approaches, where not all areas have to be funded
and the prioritization is often more specific, but it is also
not completely untargeted.
Finally, most funders mainly dispensed funding via
project grants, with smaller programmes that provide
grants to excellent individual researchers. However,
others put more focus on individual excellence. The
HHMI has traditionally been a proponent of such
people-focused funding. Since recently, other funders,
such as the Wellcome Trust and the NIH, are increas-
ingly making use of ‘people grants’ as well [36].
Funding patterns towards diseases
The funding organizations’ research expenditures to-
wards 20 specific health areas are shown in Table 5. We
could report data for at least one health area for seven
funders. However, as the table makes clear, these data
were often not available.
Funding patterns varied, with some funders showing
preferences for investing in non-communicable over
communicable diseases and others showing the opposite.
For example, the NIH spent less on infectious disease re-
search in total than on cancer research alone, while the
Wellcome Trust spent 14 times more on infectious dis-
ease research than on cancer research. Similar variations
arose when comparing more specific disease areas within
the non-communicable or communicable diseases. For
example, the NIH spent almost three times more on
cancer research than on cardiovascular research while
the EC under the FP7 programme spent roughly equal
amounts on both, and while HIV/AIDS funding com-
prised more than half of the infectious disease research
funding at the US NIH, it comprised less than 10% of that
funding at the Australian National Health and Medical
Research Council (NHMRC).
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Six funders used classification systems to classify their
funding to health areas (Table 6); five different classifica-
tion systems were used by these funders (the two fun-
ders from the United Kingdom used the same system).
Besides using different categories for health problems,
these systems also varied on other aspects, such as who
enters the data (e.g. the researcher or a specialist
employed by the funder) and whether grants can be
indexed as belonging to one or multiple health
problems. Seven funders reported amounts of funding
allocated to various research types and the same seven
reported how much funding was allocated to various re-
cipient countries or regions.
Discussion
In this article, we have identified the 10 largest funding
organizations of health research globally and shed more
light on their funding distribution mechanisms and
Table 2 Annual health research expenditures of key funders of Official Development Assistance (ODA)
Funding organization Country Year for which
funding data
were collected
Expenditures on
health research
(in million 2013 US $)
Specificity of
the funding dataa
Research area
that the funding
data refer toa
Reporting format
of the funding dataa
United States Agency
for International Development
(USAID)
USA 2012 186.4 II A 1
UK Department for International
Development (DFID)
GBR 2014 97.5 III A 2
Grand Challenges Canada CAN 2013 46.3 I A 1
Dutch Directorate General of
Development Cooperation (DGIS)
NLD 2012 11.7 I A 1
German Federal Ministry for
Economic Cooperation and
Development (BMZ)
DEU 2011 0.9 I A 1
Canadian Department of Foreign
Affairs, Trade and Development
(DFATD)
CAN 2011 0.8 I A 1
Ministère des Affaires Etrangères
et Européennes (MAEE)
FRA 2011 0.7 I A 1
L'Agence Française de
Développement (AFD)
FRA 2013 0.0 – – –
For DFID, USAID and Grand Challenges Canada data on annual health research expenditures were publicly available. For AFD data were acquired through a
personal communication. For all other organizations, no data were available or could be provided. For these organizations, annual health research expenditures
were approximated by extracting expenditure figures from G-FINDER, which is limited to health research focused on product development [54]
aSee note a under Table 1
Table 3 Annual health research expenditures of key multilateral funding organizations of health research
Funding organization Year for which
funding data
were collected
Expenditures on
health research
(in million 2013 US $)
Specificity of
the funding dataa
Research area
that the funding
data refer toa
Reporting
format of the
funding dataa
World Health Organization (WHO) 2006 135.0 I A 1
World Bank 2011 2.1 I A 1
Pan American Health Organization (PAHO) 2011 0.0 I A 1
Global Alliance for Vaccines and Immunisation
(GAVI) (including the International Finance Facility
for Immunisation (IFFIm))
2013 0.0 I A 1
Global Fund to Fight AIDS, Tuberculosis
and Malaria
2013 0.0 – – –
UNAIDS 2013 0.0 – – –
UNITAID – No data – – –
WHO data on annual health research expenditures were derived from an article by Terry et al. [55]. The Global Fund and UNAIDS data were acquired through
personal communications. For the other organizations, no data were available or could be provided. For these organizations, annual health research expenditures
were approximated by extracting expenditure figures from G-FINDER, which is limited to health research focused on product development (not available for
UNITAID) [54]. It should be noted that some of these organizations, such as the World Bank, conduct a substantial amount of health policy research every year.
Since G-FINDER’s data were the only data available on World Bank expenditures on health research, policy research expenditures have not been included
aSee note a under Table 1
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Table 4 Overview of funding distribution mechanisms of the 10 largest funding organizations of health research globally (in million 2013 US $)
1 2 2a 2b 3 4 5 5a 6 7 8 9 10
Funding
organization
NIH EC –
total
EC – FP7
health
EC – ERC MRC Insermb US
DoD
–
total
US DoD –
CDMRP
Wellcome
Trusta
CIHR NHMRC HHMI DFG
Country USA EU EU EU GBR FRA USA USA GBR CAN AUS USA DEU
Total health
research funding
26,081.3 3717.7 1181.7 783.4 1321.5 1041.2 1017.7 409.0 909.1 883.6 777.6 752.0 630.6
Year 2013 2013 2013 2013 2013 2013 2013 2012 2013 2012 2013 2013 2012
Intramural vs.
extramural
Largely
extramural
NA Extramural Extramural Mixed Intramural NA Largely
extramural
Largely
extramural
Extramural Extramural Largely
extramuralc
Extramural
Mechanism
for extramural
funding
Largely
untargeted
(but earmarked
for broad areas),
with smaller
targeted and
organizational
funding
streams
NA Targeted,
issuing
calls under
prioritized
health
research
topics
Untargeted Mixed approach,
with large
streams for
untargeted
(but
earmarked for
broad areas),
targeted and
organizational
fundingd
– NA Largely
targeted,
issuing calls
under
prioritized
health research
topics, with a
smaller
untargeted
funding
stream
Largely
untargeted,
with a
smaller
targeted
funding
stream
Largely
untargeted,
with a
smaller
targeted
funding
stream
Largely untargeted,
with smaller
organizational and
targeted funding
streams
Untargeted Mixed
approach,
with large
streams for
organizational
and untargeted
funding and a
smaller
targeted
funding
stream
Intramural funding 3283 0 0 0 513 1041 – 16 155 0 0 100 0
Extramural funding 22,799 3718 1182 783 809 0 – 393 754 884 778 652 631e
Project grants 18,341 – 1182 783 519 0 – 368 – 692 478 0 271
Untargeted 0 – 0 783 0 0 – 0 – 464 468 0 217
Untargeted,
earmarked
for broad
areas
11,708 – 0 0 220f 0 – 0 – 0 0 0 0
Targeted 3738 – 1182 0 221f 0 – 299 – 228 0 0 52
Highly
targeted
2895 – 0 0 0 0 – 69 – 0 10 0 2
‘People grants’ 615 – 0 0 98 0 – 25 – 105 156 652 14
All funding to
organizations
2709 – 0 0 163 0 – 0 – 4 143 0 254
Other researchg 1134 – 0 0 28 0 – 0 – 83 0 0 1
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Table 4 Overview of funding distribution mechanisms of the 10 largest funding organizations of health research globally (in million 2013 US $) (Continued)
Research training/
science educationh
768 – 0 0 0 0 – 26 – 64 0 80 38
All data are from publicly available documents, except for CDMRP and DFG, for which data were received through personal communication, and for CIHR for which the data were largely publicly available but were
supplemented through personal communication
Zero’s (“0”) indicates an amount of zero million in funding; dashes (“–”) indicate that no information on the amount of funding was available; NA indicates that we did not extract information for overarching funding
organizations (only for the more specific organization(s) next to it). Some of the funders we identified (the EC and the US DoD) consisted of several sub-organizations that distributed the research funding in different
ways, in which case we compiled total funding for the organization as a whole, but analysed the distribution mechanisms of the largest sub-organization(s)
NIH, National Institutes Of Health; EC, European Commission; FP7 health, FP7-cooperation programme – Health Theme; ERC, European Research Council; US DoD, United States Department Of Defense; CDMRP,
Congressionally Directed Medical Research Program; MRC, Medical Research Council; Inserm, Institut national de la santé et de la recherche médicale; CIHR, Canadian Institutes Of Health Research; NHMRC, National
Health and Medical Research Council; HHMI, Howard Hughes Medical Institute; DFG, Deutsche Forschungsgemeinschaft
aThe annual expenditures for the Wellcome Trust are a slight overestimation for health research spending. Under medical humanities and engagement, various non-research grants are provided as well as other
activities (e.g. running the Wellcome library), but these were not reported on separately, so are included under ‘Research’
bInserm funds research almost exclusively intramurally. However, Inserm does provide for some extramural funding. We were not able to find any information about the proportion of funding by Inserm that is
distributed extramurally, but it is likely very small, so we classified all of Inserm’s funding as intramural. Historical research into Inserm’s expenditures put the organization’s intramural/extramural proportions of
distributed funds at 10/90 [23]
cTechnically, HHMI funds research 100% intramurally because it employs its own researchers. However, its researchers are mostly located at external research institutes or universities (with the exception of HHMI’s
Janelia Research Campus), and therefore, for this table, we classified HHMI’s funding distribution mechanism as largely extramural. The 100 million dollar for intramural funding is based on an annual budget estimate
from 2010 for the Janelia Research Campus by HHMI itself and is not a precise number
dThe MRC has both untargeted and targeted funding streams; most are untargeted (‘response-mode’ in the MRC’s description). However, untargeted funding at the MRC is not fully untargeted, the Research Boards
that make funding decisions take into account broader strategic considerations, priorities, portfolio balance, and issue ‘highlight notices’ for issues that are of especial importance to the MRC
eThe data for DFG do not add up because multiple sources were used (public reporting and personal communication). The total amount of funding includes overhead costs for projects, while amount for various
research categories are exclusive of overhead costs
fFunding distribution figures of MRC are based on data provided in the annual report 2013/2014 of the MRC United Kingdom. All figures are based on actual expenditures; however, targeted and untargeted funding
are based on commitments made, and therefore do not add up to total Project funding
g‘Other research’ included ‘other research’ categories in funding organizations’ reports and funds for research communication when specified separately
hTraining support and research education were not included in the overall amount for health research expenditures, but because there can be an overlap between these activities and research activities, particularly in
the case of post-doctoral fellowships, we collected expenditures toward research education and training separately
For definitions of terms in this table (e.g. ‘people grants’ or ‘untargeted’/‘targeted’/‘highly targeted’) see Additional file 1
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Table 5 Overview of funding provided by the 10 largest funders of health research globally to 20 selected health areas (in million 2013 US $)
1 2 2a 2b 3 4 5 5a 6 7 8 9 10
Funding organization NIH EC –
total
EC – FP7
health
EC –
ERC
MRC Inserm US DoD –
total
US DoD –
CDMRP
Wellcome
Trust
CIHR NHMRC HHMI DFG
Country USA EU EU EU GBR FRA USA USA GBR CAN AUS USA DEU
Year 2013 – 2013 – 2009/
2010
– – 2012 2009/2010 2012 2013 – –
Communicable, maternal, neonatal, and nutritional
disorders
– – – – – – – – – – 179 – –
Infectious diseases 4887 – 186 – 168 – – – 171 242 127 – –
Lower respiratory infections 113 – – – – – – – – – 14 – –
Diarrheal diseases – – – – – – – – – – 8 – –
HIV/AIDS 2898 – – – – – – – – 46 12 – –
Maternal disorders – – – – 30 – – – 14 – 32 – –
Maternal haemorrhage – – – – – – – – – – – – –
Neonatal disorders 486 – – – – – – – – – 19 – –
Pre-term birth complications 198 – – – – – – – – – 15 – –
Nutritional deficiencies – – – – – – – – – – 2 – –
Protein deficiencies – – – – – – – – – – – – –
Non-communicable diseases – – – – – – – – – – – – –
Cardiovascular and circulatory diseases 1964 – 82 – 50 – – 13 28 40 97 – –
Ischemic heart disease 404 – – – – – – – – – 30 – –
Neoplasms 5274 – 80 – 84 – – – 12 – 139 – –
Trachea, bronchus, lung cancer 208 – – – – – – – – – 6 – –
Mental health 2174 – – – 59 – – – 29 55 59 – –
Unipolar depressive disorder 415 – – – – – – – – – 22 – –
Injuries 367 – – – 1 – – – 0 – 35 – –
Transport injury – – – – – – – – – – 2 – –
Zero’s (“0”) indicates an amount of zero million in funding; dashes (“–”) indicate that no information on the amount of funding was available. Health areas were chosen to be a representative sample of health areas in
the Global Burden of Disease (GBD) classification [34]. Adding spending on the various health areas per funder will not total to the funder’s total expenditures, because the categories are a selection of health areas
from the GBD report. Funding for selected health areas needs to be interpreted with caution because these data are mutually exclusive for some funders (Wellcome, MRC, CIHR, EC FP7 health, CDMRP), but not for
others (NIH, NHMRC)
See Table 4 for funders’ abbreviations
Sources: NIH, http://report.nih.gov/categorical_spending.aspx; EC FP7 Cooperation Progamme Health theme, http://www.healthcompetence.eu/; MRC and Wellcome Trust taken from the United Kingdom Health
Research Analysis 2009/10 (United Kingdom Clinical Research Collaboration, 2012) (http://www.ukcrc.org/research-coordination/health-research-analysis/uk-healthresearch-analysis/3 and http://www.hrcsonline.net/
pages/data); CDMRP, funding categorisation based on “physiology classification system” that we were provided by CDMRP through personal communication; CIHR, data received through personal communication;
NHMRC, http://www.nhmrc.gov.au/grants/research-funding-statistics-and-data/funding-datasets . Funding for selected health problems was only reported if funders categorized grants using an indexing system,
amounts for various targeted programmes were not included, with the exception of the EC FP7 Cooperation programme, health theme, who requested we use programme-based figures for annual commitments
from HealthCompetence.eu
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funding patterns. Two main conclusions can be drawn
from this mapping of influential funders of health
research.
Differences between funding organizations: the need for
more evaluation of funding distribution models
First, there is considerable diversity between funding or-
ganizations in terms of what they fund and how they
distribute those funds. This begs the question: do some
funding distribution models have more impact than
others? The impact of different approaches to funding
health research is regularly discussed in the literature,
for example, for intramural versus extramural funding
[23], for targeted versus untargeted funding [37], for
‘people grants’ versus project grants [36, 38], for small
grants versus large grants [10], and for competitive ver-
sus non-competitive research funding [39]. However,
comparative evaluations of the impact of various funding
models are scarce [10, 23, 38], even though approaches
to measure the impact of health research are available
[40]. An exception has been the recent comparisons of
‘people grants’ versus projects grants in the United States,
which compared HHMI with NIH researchers and NIH
Pioneer Awards with NIH project grants [36, 41–43].
These comparisons have led the NIH to consider a broad
shift toward ‘people grants’, demonstrating the value and
potential impact of such evaluations [36]. Evaluations of
this kind provide new insights when comparing funding
models across funding organizations, but given the differ-
ent contexts in which funders operate, comparing the im-
pact of different models within one funding organization
is perhaps particularly valuable and should become more
common practice.
There is also a need for more debate about where the
power to decide priorities for publicly funded health re-
search should lie (with parliaments, ministries, funding
agencies, or independent committees of experts). Such
debate is needed because there are finite resources for
investing in health research and thus priorities need to
be set using fair and legitimate methods and using the
best possible evidence [44]. In practice, public sector
health research funding decisions are not only made on
the basis of what research is needed, but are regularly in-
fluenced by other factors, such as political interests, ad-
vocacy and lobbying [2]. Thus, there is a need for
transparency on who makes those decisions and to de-
bate who should make them [2, 13, 45–47]. Analysis of
funding organizations’ priority setting processes was not
part of this study (see Limitations) but deserves to be a
more frequent subject of research studies in the future.
Table 6 Funding organizations’ use of classification systems for reporting health research expenditures
Funding organization Country Health categories Recipient countries
or regions
Type of research Data classification system
for health categories
1 NIH USA Yes Yes Yes RCDC
2 EC EU No No No –
2a FP7 Cooperation programme, health theme EU No Yes Yes –
2b ERC EU No No No –
3 MRC GBR Yes Yes Yes HRCS (modified ICD-10)
4 INSERM FRA No – – –
5 US DoD USA No – – –
5a CDMRP USA Yes Yes Yes "Physiology" classificationb
6 Wellcome Trust GBR Yes Yes Yes HRCS (modified ICD-10)
7 CIHR CAN Yesa Yes Yes EIS Research Area and Research
Class taxonomy in Research
Reporting systema
8 NHMRC AUS Yes Yes Yes ANZSRC (modified ICD-10)
9 HHMI USA No – – –
10 DFG DEU No No No –
“–” means that we were not able to find information for this field
See Table 4 for funders’ abbreviations. ANZSRC, Australian and New Zealand Standard Research Classification; EIS, Electronic Information System; HRCS, Health
Research Classification System; ICD, International Classification of Diseases; RCDC, Research, Condition, and Disease Categorization
aAt the time of data collection, CIHR was in the process of implementing its data classification system. It did not publicly report data yet on how much funding
goes to various health areas, but noted that it would do so in the future. CIHR was able to provide us with data for several health areas via personal
communication. The organization noted through the same personal communication that, in terms of classifying or reporting on the research that it funds, CIHR
uses the EIS Research Area and Research Class in-house menu, Institute in-house Keyword lists, the Thompson Reuters Fields and Sub-Fields, and MESH. The
Research Reporting system uses the EIS Research Area and Research Class taxonomy (http://www.cihr-irsc.gc.ca/e/45318.html)
bThis classification was sent to us by CDMRP upon request. All other classifications are publicly available
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Improving publicly available data on health research
funding
Second, to enable evaluation and debates as noted above,
it is necessary to have a map of the health research fund-
ing landscape: to know who the main funders of health re-
search are, what they fund, and how they decide what gets
funded [2, 6–11, 13]. Yet, this study shows that these data
are often not available. Through our study, we did not find
a list of all public or philanthropic health research funders
worldwide that included their annual health research ex-
penditures (Additional file 1). Therefore, we have now
established such a list ourselves at www.healthresearch-
funders.org. On this website, we provide access to the data
collected for this article and to information on more than
200 other public and philanthropic funders of health re-
search that we have added to this website since the map-
ping for this article was completed.
Besides the absence of a global listing of funding orga-
nizations, we found that data on organizations’ funding
patterns and funding distribution mechanisms are often
not available, and when they are, they are difficult to ag-
gregate, owing to differences in funders’ data classifica-
tion systems. Notably, we only collected these data for
the 10 largest funding organizations of health research.
The absence of such information, and the difficulties in
aggregating the data across funders, are likely to be more
prominent when smaller funders are also included.
There is currently no consensus on a framework for pro-
ducing descriptive data on funders’ funding patterns
(both in terms of health areas and research types) nor
on a framework for describing their funding distribution
mechanisms [6, 8, 37]. In this article, we have proposed
three frameworks for reporting data on health research
funding: for reporting data on funding distribution
mechanisms (Table 4), for reporting data on funding
patterns in terms of health problems (the Global Burden
of Disease classification [34]), and for reporting data on
funding patterns in terms of research types (biomedical
research, clinical research, epidemiological research or
health systems research, as proposed by Frenk [35]).
The adoption of standards for reporting funding data,
including guidance on what data classification systems
to use, by funding organizations, for example through
collaborative initiatives such as the Heads of Inter-
national Research Organizations, would substantially
improve the quality and comparability of reported fund-
ing data [9].
Funding organizations are starting to support the goal
of transparency and are increasingly recognizing the prob-
lems noted above and addressing them. At the 2014
World Health Summit in Berlin, several major funders of
health research expressed interest to work together to-
ward developing a common approach for mapping health
research funding flows [12]. Another good example of a
multi-funder collaboration to increase insight in health re-
search investments is the World RePORT website [48].
On a national level, the United Kingdom has led the way
in terms of harmonized reporting by showing it is feasible
to collect comparable data on health research funding
from all major public funding bodies and charities in a
country [22]. Besides initiatives from funders themselves,
there are also several promising initiatives from other par-
ties to address the lack of data on global health research
funding [1, 16, 49–51]. The recent decision to establish a
Global Observatory on Health R&D at WHO in particular
may help to improve transparency in this area [1].
Limitations
Finally, we note that the mapping conducted for this art-
icle has had several limitations. First, we have excluded
funding organizations in the private for-profit sector
(these are listed elsewhere [30]). Second, national sys-
tems for funding health research vary. In many coun-
tries, a large amount of health funding is dispersed
directly from governments to universities or research in-
stitutes via block grants. We excluded these block grants
and therefore the public funding organizations that we
report on do not all contribute the same share of all
health research that is publicly funded in a country.
Third, we had to make several generalizations in order
to be able to report data across funders that were diverse
in their funding distribution mechanisms and reporting
systems. For instance, what we have termed ‘targeted’ re-
search funding, is a grey area that ranges from broad
prioritized research areas to specific research topics or
questions [52]. Also, funders reported on their expendi-
tures on health research in various formats. Although
we have kept track of these varying reporting formats,
they decrease comparability across funders. Fourth, we
would have liked to exclude overhead costs within pro-
ject funding (not operational costs of the funder, which
we did exclude where possible, but overhead costs of the
research organization), to measure only the amount of
funding that went to research, but this was not feasible
because it was mostly not reported. Fifth, our proposed
framework for reporting on funders’ funding distribution
mechanisms (Table 4) lacks detail. It would have been
interesting to also report on more detailed mechanisms,
such as funders’ grants for businesses and PDPs/PPPs,
but we did not include such analyses because of a lack
of comparable data across funders. Sixth, funding orga-
nizations frequently make adaptations to their funding
strategies, and therefore our findings should be viewed
as a snapshot of funders’ expenditures, funding distribu-
tion mechanisms and funding patterns during the time
of our data collection [53]. Seventh, in addition to
reporting about funding organizations’ funding distribu-
tion mechanisms and patterns, we would have liked to
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report on funding organizations’ priority setting pro-
cesses as part of this work (another important aspect of
how funders decide what gets funded). However, we found
that priority setting processes were generally not well-
described and highly variable across funders, making it
difficult to analyse and report our data. It deserves recom-
mendation that such an analysis is conducted in the future,
but the development of a framework for assessing priority
setting processes at funders is needed first, potentially
based on existing guidance for health research priority set-
ting [44]. Lastly, and most importantly, our search strategy
was limited in scope (see for more detail Additional file 1),
was aimed only at finding the 10 largest funding organiza-
tions of health research in the world, and detailed data were
only collected for those 10 organizations.
Conclusions
This study identified the 10 largest funding organizations
of health research in the world and showed that these
organizations together fund research for $37.1 billion,
40% of all public and philanthropic health research
spending globally. It also mapped the funding patterns
and funding distributions mechanisms of these funders
and showed that there is considerable diversity between
organizations in terms of what they fund and how they
distribute those funds, highlighting the need for com-
parative evaluations of the impact of different funding
distribution models. Moreover, because many of the data
we tried to collect were not available, our study demon-
strates that there is a need for increased transparency on
who the largest funding organizations of health research
are, what they fund, and how they decide what gets
funded. As a first step in improving transparency in this
area, we have proposed frameworks for reporting on
funding patterns (in terms of health problems and re-
search types) and for reporting on funding distribution
mechanisms in this article and have established
www.healthresearchfunders.org, where we list more than
250 public and philanthropic funders of health research
and their annual health research expenditures. We will
further expand and update this list of funding organiza-
tions in the future and welcome both suggestions and
data from all who wish to help us make this database
more accurate and more inclusive.
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